EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. | Read by QxMD (original) (raw)
Journal Article
Research Support, Non-U.S. Gov't
Review
Systematic Review
Werner Kempf, Katrin Pfaltz, Maarten H Vermeer, Antonio Cozzio, Pablo L Ortiz-Romero, Martine Bagot, Elise Olsen, Youn H Kim, Reinhard Dummer, Nicola Pimpinelli, Sean Whittaker, Emmilia Hodak, Lorenzo Cerroni, Emilio Berti, Steve Horwitz, H Miles Prince, Joan Guitart, Teresa Estrach, José A Sanches, Madeleine Duvic, Annamari Ranki, Brigitte Dreno, Sonja Ostheeren-Michaelis, Robert Knobler, Gary Wood, Rein Willemze
Blood 2011 October 13
Primary cutaneous CD30(+) lymphoproliferative disorders (CD30(+) LPDs) are the second most common form of cutaneous T-cell lymphomas and include lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Despite the anaplastic cytomorphology of tumor cells that suggest an aggressive course, CD30(+) LPDs are characterized by an excellent prognosis. Although a broad spectrum of therapeutic strategies has been reported, these have been limited mostly to small retrospective cohort series or case reports, and only very few prospective controlled or multicenter studies have been performed, which results in a low level of evidence for most therapies. The response rates to treatment, recurrence rates, and outcome have not been analyzed in a systematic review. Moreover, international guidelines for staging and treatment of CD30(+) LPDs have not yet been presented. Based on a literature analysis and discussions, recommendations were elaborated by a multidisciplinary expert panel of the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer, the International Society for Cutaneous Lymphomas, and the United States Cutaneous Lymphoma Consortium. The recommendations represent the state-of-the-art management of CD30(+) LPDs and include definitions for clinical endpoints as well as response criteria for future clinical trials in CD30(+) LPDs.
We have located links that may give you full text access.
All material on this website is protected by copyright, Copyright © 1994-
2024
by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our
and
